And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...